Company
Janus Henderson Investors
Investments
| Company | Round | Date | Lead |
|---|---|---|---|
| Epicrispr Biotechnologies | Series C | 2026-08-11 | Lead |
| Claris Biotherapeutics, Inc. | Series B | 2026-08-03 | |
| Lycia Therapeutics | Series D | 2026-06-29 | Lead |
| Triveni Bio | Series C | 2026-06-17 | Lead |
| Oak Hill Bio | Series A | 2026-06-03 | Lead |
| Ray Therapeutics | Series B | 2026-04-21 | Lead |
| Calyxo, Inc. | Series F | 2026-04-14 | Lead |
| Poplar Therapeutics | Series A | 2026-03-04 | Lead |
| ILiAD Biotechnologies | Series B | 2026-02-11 | |
| CesiumAstro | Series C | 2026-02-02 | |
| TRexBio | Funding | 2026-01-27 | |
| Diagonal Therapeutics | Series B | 2026-01-09 | Lead |
| Parabilis Medicines | Series F | 2026-01-08 | Lead |
| BlossomHill Therapeutics | Series B | 2025-12-16 | Lead |
| Star Therapeutics | Series D | 2025-10-01 | |
| Galvanize Therapeutics | Series C | 2025-09-03 | |
| Curevo | Series B | 2025-03-17 | |
| nChroma Bio | Financing | 2024-12-12 | |
| Metsera | Series B | 2024-11-14 | |
| Aktis Oncology | Series B Funding | 2024-09-30 | Lead |
| Asher Bio | Series C Funding | 2024-04-17 | Lead |
| Parse Biosciences | Series C + debt facility | 2023-12-14 | |
| Carmot Therapeutics | Series E Equity Financing | 2023-05-31 | |
| Heartflow, Inc. | Series F Funding | 2023-04-06 | |
| Chroma Medicine | Series B Financing | 2023-03-01 |